JBC Avanti Polar Lipids

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kakizawa, T.
Right arrow Articles by Hashizume, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kakizawa, T.
Right arrow Articles by Hashizume, K.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

J Biol Chem, Vol. 274, Issue 27, 19103-19108, July 2, 1999


Functional Interaction between Oct-1 and Retinoid X Receptor*

Tomoko KakizawaDagger , Takahide Miyamoto, Kazuo Ichikawa, Atsuko Kaneko, Satoru Suzuki, Masahiro Hara, Takeshi Nagasawa, Teiji Takeda, Jun-ichiro Mori, Mieko Kumagai, and Kiyoshi Hashizume

From the Department of Geriatrics, Endocrinology, and Metabolism, Shinshu University School of Medicine, Matsumoto 390-8621, Japan

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The retinoid X receptor (RXR) is a member of the nuclear hormone receptor superfamily and heterodimerizes with a variety of other family members such as the thyroid hormone receptor (TR),1 retinoic acid receptor, vitamin D receptor, and peroxisome proliferator-activated receptor. Therefore, RXR is supposed to play a key role in a ligand-dependent regulation of gene transcription by nuclear receptors. In this study, we have identified the octamer-binding transcription factor-1 (Oct-1) as a novel interaction factor of RXR. In vitro pull-down assays using RXR deletion mutants showed that the interaction surfaces were located in the region encompassing the DNA binding domain (C domain) and the hinge domain (D domain) of RXR. We also showed that RXR interacted with the POU homeodomain but not with the POU-specific domain of Oct-1. Gel shift analysis revealed that Oct-1 reduced the binding of TR/RXR heterodimers to the thyroid hormone response element (TRE). In transient transfection assays using COS1 cells, Oct-1 repressed the T3-dependent transcriptional activity of TR/RXR heterodimers, consistent with in vitro DNA binding data; however, transcriptional activation by Gal4-TR(LBD) (LBD, ligand binding domain), which lacks its own DNA binding domain but retains responsiveness to T3, was not influenced by Oct-1. These results suggest that Oct-1 functionally interacts with RXR and negatively regulates the nuclear receptor signaling pathway by altering the DNA binding ability of the receptors.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The steroid/thyroid hormone receptor superfamily is a large group of related transcriptional factors that control cellular differentiation, development, and homeostasis by direct interaction with distinct cis-elements in target genes (1, 2). This superfamily includes receptors for steroids, thyroid, vitamin D3, retinoids, and a large number of orphan receptors whose cognate ligands are still unknown (3). Members of the superfamily are characterized by a highly conserved cysteine-rich DNA binding domain containing two zinc finger structures necessary for sequence-specific DNA interaction (4). The complex carboxyl-terminal region of the receptors contains ligand binding, receptor dimerization, and putative transcriptional activation function (5). Members of the superfamily regulate transcription by binding to response elements containing two or more copies (often degenerate) of the consensus motif AGGTCA (6, 7). Recently it was shown that retinoic acid receptor, TR, VDR, and peroxisome proliferator-activated receptor form heterodimers with the RXR on bipartite hormone response elements composed of non-symmetrical head-to-tail tandem AGGTCA "half-sites" (8-10). More than half of the orphan receptors have been shown to heterodimerize with RXR (3). Thus, RXRs are supposed to play a key role in ligand-dependent transcriptional activity of nuclear receptors.

The mechanisms by which nuclear hormone receptors regulate target gene transcription are currently under intensive investigation. The ligand-activated nuclear receptors may promote formation of preinitiation complex of the basal transcriptional apparatus and facilitate transcription by RNA polymerase II. Recently, a number of nuclear receptor-associated proteins have been identified that interact with receptors and regulate their transcriptional activities. A nuclear receptor co-repressor, N-CoR or a related factor SMRT, binds to unliganded receptors and acts as a transcriptional silencer of nuclear receptors (11-13). It has been shown that N-CoR and SMRT recruit mSin3 and mRPD3 that possess histone deacetylase activity and make the chromatin transcriptionally inactive (14). When ligands bind to receptors, the co-repressor complex dissociates, and a co-activator complex containing N-CoA1/SRC-1, CBP/p300, and p/CAF associates with the receptors (15-21). Interestingly, these complexes have histone acetyltransferase activity and make the chromatin unwind, resulting in the transcriptionally active state (22-24).

Although recent extensive studies have depicted a model of nuclear receptor action, it is still not enough to explain the divergent biological effect of nuclear hormone receptors in development, differentiation, and cell cycle regulation. Therefore, it is reasonable to speculate that a large number of novel factors may associate with nuclear receptors. By using a biochemical technique, we have identified the octamer-binding transcription factor-1 (Oct-1) as a novel interaction factor of RXR. Oct-1 is ubiquitously expressed and activates the octamer motif containing promoters which has been shown to be related to cell cycle regulation of the human histone H2B gene and the constitutive expression of small nuclear RNA genes (25-27). Oct-1 is a member of a family of transcription factors characterized by the presence of a bipartite DNA binding domain, the POU domain (28, 29). This POU domain consists of two conserved regions, a POU-specific domain and a POU homeodomain. Both subdomains have a helix-turn-helix motif and act as the DNA binding domain but are also involved in protein-protein interactions. A number of transcription factors have been identified to interact with the POU domains of Oct-1 and/or Oct-2, e.g. TBP, TFIIB, HMG2, and the lymphoid-specific transcriptional co-activator OBF-1 (30-34). Oct-2 has a highly similar POU domain to Oct-1 and is expressed in a B cell-specific pattern and has a distinct transcriptional regulatory potential (35-37). In this study we have demonstrated a novel interaction of RXR with Oct-1/2 through their DNA binding domains. The POU domain of Oct-1/2 has influenced the RXR/TR heterodimers binding to thyroid hormone response element (TRE). Furthermore, these interactions negatively regulated the transcriptional activity of the TRE-containing promoter.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Isolation of Interacting Proteins-- Rat GH3 cDNA library was constructed using T7 expression phage and screened by a full-length human RXRalpha as a probe. Isolated clones were subcloned into pGEM 3 and sequenced by Applied Biosystems 3300 autosequencer. [35S]Methionine-labeled peptides were produced using the T7 TNT-coupled system (Promega), and their interactions with RXRalpha were confirmed by pul- down experiment using matrix-bound glutathione S-transferase (GST)-RXRalpha . About 1 × 106 clones were screened, and one clone that corresponds to human Oct-1 cDNA containing amino acid residues 371-438 was confirmed as an interacting partner with RXR.

Plasmid Constructions-- The Oct-1/2 expression vectors pcDNA3HA Oct-1/2 were gifts from Dr. H. Singh (see Ref. 38). The in vitro transcription and translation vector for Oct-1 p6His Oct-1 was from Dr. R. G. Roeder (see Ref. 39), and pBS Oct-1+ was from Dr. W. Herr (see Ref. 26). The eukaryotic GST expression plasmid for Oct-1 POU domain, POU-homeodomain, and POU-specific domain were gifts from Dr. van der Vliet (see Ref. 40).

The RXRalpha and VDR cDNA were gifts from Dr. R. M. Evans ( see Ref. 41) and Dr. B. O'Malley (see Ref. 42), respectively. To construct the bacterial expression vector for GST fusion proteins, PCR-amplified full-length RXRalpha , TRalpha 1 (43), and VDR cDNA were inserted in frame into BamHI and EcoRI cloning sites of the pGEX-2T vector (Amersham Pharmacia Biotech). The following oligonucleotides were used to amplify the full-length human RXRalpha : forward primer, 5'-agatctcatATGGACACCAAACATTTCCTG-3', and reverse primer, 5'-gaattcTAAGTCATTTGGTGCGGC-3'; TRalpha 1, forward primer, 5'-atcggatccATGGAACAGAAGCCAAGCAAG-3', and reverse primer, 5'-atcgaattcTTAGACTTCCTGATCCTC-3'; and VDR, forward primer, 5'-atcggatccATGGAGGCAATGGCGGCC-3', and reverse primer, 5'-atcgaattcCTCAGGAGATCTCATTGCC-3'. AP-2 cDNA was a gift from Dr. R. Tjian (see Ref. 44). To construct the bacterial expression vector for GST fusion protein of AP-2, PCR-amplified full-length AP-2 cDNAs were inserted in frame into EcoRI- and SalI-cloning sites of the pGEX-6P1 vector (Amersham Pharmacia Biotech). The following oligonucleotides were used to amplify the full-length AP-2: forward primer, 5'-ctcgaattc ATGCTTTGGAAATTGACG-3', and reverse primer, 5'-ctcgtcgacTCACTTTCTGTGCTTCTC-3'. TRalpha 1 expression vector, pCDM TRalpha 1 was described previously (45).

The Palx2 TK luciferase gene contains two copies of a palindromic TRE upstream of the thymidine kinase (TK) promoter in the PA3 luciferase vector (46). The rGH chloramphenicol acetyltransferase reporter plasmid that contains rat growth hormone promoter region spanning from -237 to +8 from the transcription start site was a gift from D. D. Moore (see Ref. 47). To construct the mammalian expression vector for Gal4 DBD fusion protein, PCR-amplified ligand binding domain of TRalpha 1 was inserted in frame into BamHI- and SalI-cloning sites of the pM vector (CLONTECH). The following oligonucleotides were used to amplify the TRalpha 1 LBD: forward primer, 5'-atcggaattc ATGGCCATGGACTTGGTTCT-3', and reverse primer, 5'-gatcgtcgacTTAGACTTCCTGATCCTCAA-3'. UASx4 TK luc reporter plasmid was gift from Dr. R. M. Evans (see Ref. 48).

Cell Culture and Transient Transfection and Reporter Assays-- COS1 cells were grown in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum, 100 units/ml penicillin G, and 0.25 mg/ml streptomycin at 37 °C in 5% CO2. Transfection was done in COS1 cells using the standard calcium phosphate procedure. Typically, 0.25 µg of Palx2-driven luciferase reporter was co-transfected with 100 ng of the indicated expression vectors. Cells were incubated for 12 h, and the medium on the cells was replaced with fresh medium and 10-7 M T3 was added. Cells were harvested after 12 h. beta -Galactosidase activity was measured by the method previously described using chlorophenol red-beta -D-galactopyranoside as a substrate (49). Luciferase assays were performed using the PicaGene Luciferase Assay System (Toyo Inki, Tokyo, Japan). Luciferase activity was determined using Lumat LB9501 (Berthold Japan K.K., Tokyo, Japan) and was expressed as relative light units normalized to the beta -galactosidase activity. Chloramphenicol acetyltransferase activities were measured as described previously (50) and quantitated by PhosphorImager. Each transfection was conducted in triplicate, and data represent the mean ± S.D. of more than three individual experiments.

In Vitro Transcription and Translation-- Coupled transcription and translation of Oct-1/2 RXR were carried out using a T7 TNT in vitro transcription/translation kit (Promega) according to the manufacturer's instructions.

Overnight cultures of Escherichia coli BL21 carrying the recombinant GST-RXRalpha and GST control plasmids were diluted 100-fold, cultured for 5-6 h, and then induced with 0.1 mM isopropyl beta -D-thiogalactopyranoside. After another 3 h, bacteria were collected and then washed with PBS. Pellets were suspended in PBS containing 1% (v/v) Triton X-100 and were then sonicated. Debris was removed by centrifugation. The fusion protein or the GST control protein was bound to glutathione-Sepharose (Amersham Pharmacia Biotech) and extensively washed with PBS containing 1% (v/v) Triton X-100. Matrix-bound proteins were used for interaction experiments.

GST Pull-down Assay-- 10 µl of GST-Sepharose beads containing 2-5 µg of GST recombinant proteins were incubated with [35S]methionine-labeled proteins for 1 h at 4 °C. Complexes were then centrifuged, washed three times in gel shift buffer, and separated by SDS-polyacrylamide gel electrophoresis. Radiolabeled signals were visualized and quantified using a PhosphorImager (Fuji BAS 1500). DNase I (5 units/ml) was added to the reaction in experiments shown in Fig. 1B.

Gel Retardation Assay-- Synthetic oligonucleotides representing each strand of the sequences were purified by polyacrylamide gel electrophoresis, eluted, and annealed. Double-stranded oligonucleotides were radiolabeled with dCTP (>3300 Ci/mmol; ICN, Costa Mesa, CA) by fill in reactions using Klenow large fragment DNA polymerase. Radiolabeled probes (10 fmol, 20,000-30,000 cpm) were then incubated with binding proteins in 30 ml of reaction mixture containing 10 mM KPO4, pH 8.0 buffer, 1 mM EDTA, 80 mM KCl, 1 µg of poly(dI-dC), 1 mM dithiothreitol, 0.5 mM MgCl2, 5 µg of bovine serum albumin, 10% glycerol, 1 mM phenylmethylsulfonyl fluoride, 2 mg/ml aprotinin, 1 mM leupeptin, 1 mM pepstatin. These reactions were incubated for 30 min at room temperature and analyzed on a 5% non-denaturing polyacrylamide gel in TAE buffer. Electrophoresis was performed at a constant voltage of 200 V at 4 °C in the same buffer.

Expression of Recombinant Proteins-- To express the fusion proteins with GST, PCR-amplified full-length RXRalpha cDNA or truncated fragments were inserted in frame into BamHI- and EcoRI-cloning sites of the pGEX-2TK vector (Amersham Pharmacia Biotech). Overnight cultures of E. coli BL21 carrying the recombinant GST fusions or GST control plasmid were diluted 100-fold, cultured for 5-6 h, and then induced with 0.1 mM isopropyl beta -D-thiogalactopyranoside. After another 3 h, bacteria were collected and washed with PBS. Pellets were suspended in PBS containing 1% (v/v) Triton X-100 and sonicated. Debris was removed by centrifugation. The fusion protein or the GST control protein was bound to glutathione-Sepharose (Amersham Pharmacia Biotech) and extensively washed with PBS containing 1% (v/v) Triton X-100. Matrix-bound proteins were used for interaction experiments.

Interaction Experiments-- In vitro translated 35S-labeled proteins (1-2 µl) were incubated for 20 min at room temperature with glutathione-Sepharose (10 µl) preloaded with GST fusion or GST control protein in 250 µl of binding buffer (20 mM Tris-Cl, pH 7.8, 100 mM NaCl, 10% glycerol, 1 mM dithiothreitol, 1 mM EDTA, 1 mM phenylmethanesulfonyl fluoride, 1 mM leupeptin, 1 mM pepstatin, 2 mg/ml aprotinin) in the presence or absence of 10-6 M of T3. After extensive washing with binding buffer, bound proteins were eluted in 25 µl of Laemmli sample buffer, boiled for 10 min, and resolved by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (10%) followed by autoradiography. The results of the in vitro reactions and the amount of 35S-labeled protein bound by GST fusions were visualized and quantified using a PhosphorImager (Fuji BAS 1500).

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Isolation of Oct-1 as a Interacting Protein with RXR-- In order to identify the interacting protein with RXR, we used biochemical methods. Rat GH3 cell cDNA library was screened with GST fusion containing full-length human RXRalpha as a probe. Positive clones were transcribed by T7 RNA polymerase, translated into 35S-labeled peptides using [35S]methionine, and used for pull-down experiments with GST-RXRalpha to confirm the interactions. One positive clone was identified, and the nucleotide sequences were determined. Sequence homology searches in GenBankTM revealed that the isolated clone contained the POU homeodomain of rat Oct-1 cDNA, which was highly homologous to the human Oct-1 amino acid residues 371-438.

Oct-1 Interacts with CD Domain of the RXR-- To examine the interaction between Oct-1 and RXR, we used the matrix-bound fusion protein of glutathione S-transferase with RXR (GST-RXR) for in vitro pull-down assay. As shown in Fig. 1A, [35S]methionine-labeled in vitro translated Oct-1 interacted with GST-RXR but not GST alone, and GST-RXR did not retain any of the in vitro translated control luciferase protein. As shown in Fig. 1B, addition of DNase I in the binding mixture did not alter the association of Oct-1 to matrix-bound RXR, indicating that the protein-protein interaction was not due to the presence of contaminating DNA. Reciprocal pull-down experiment was performed to confirm the interaction between RXR and Oct-1. As shown in Fig. 1C, matrix-bound GST-POU domain (3rd lane) and POU homeodomain (5th lane) specifically retains [35S]methionine-labeled RXR, whereas GST alone (lane 2) or GST-POU-specific domain (4th lane) did not.


View larger version (33K):
[in this window]
[in a new window]
  		Fig. 1.   Oct-1 interacts with RXR in vitro. A, 35S-labeled Oct-1 (amino acids (a.a.) 371-438) or luciferase was synthesized by in vitro translation and was incubated separately with GST (2nd and 5th lanes) or GST-RXR (3rd and 6th lanes) bound to glutathione-Sepharose beads. 10% of the 35S-labeled proteins added to the incubations is indicated (1st and 4th lanes). B, [35S]methionine-labeled in vitro translated Oct-1 was incubated with matrix-bound GST-RXR in the absence (1st lane) or presence (2nd lane) of DNase I. C, [35S]methionine-labeled in vitro translated RXRalpha was incubated with matrix-bound GST-POU domain (lane 3), GST-POU-specific domain (lane 4), or GST-POU homeodomain (lane 5). Matrix-bound GST was used as a control (lane 2), and 10% of the 35S-labeled protein added to the incubations is indicated (lane 1).

We next examined the specific domains in RXR that interact with Oct-1. A series of deletion mutants of GST fusion proteins representing overlapping portions of RXR (Fig. 2A) were expressed in bacteria, purified, and used to bind 35S-labeled full-length Oct-1. As shown in Fig. 2B, the DNA binding domain (C domain) and hinge domain (D domain) of RXR were required for the interaction. The C domain itself possessed only weak binding activity to the Oct-1 (lane 5), and an additional hinge domain (D domain) was necessary for full interaction (lane 6), although the D domain itself had no binding activity (lane 7). It was not surprising that the highly conserved DNA binding domain of nuclear receptors could also serve as a site for binding of co-regulator proteins. We identified the nuclear protein Oct-1 as a binding protein for the CD regions of RXR.


View larger version (33K):
[in this window]
[in a new window]
  		Fig. 2.   Domains within nuclear receptor required for Oct-1 interactions. A, series of amino- and carboxyl-terminal deletions of RXR used in pull-down experiments. B, bacterially produced GST-RXR deletions or GST alone were bound to glutathione-Sepharose beads and incubated with equivalent amounts of 35S-labeled Oct-1 produced by in vitro translation. Associated proteins were analyzed by 10% SDS-polyacrylamide gel electrophoresis and visualized by BAS 1500 (Fuji, Tokyo, Japan).

Oct-1 Inhibits the Binding of TR/RXR Heterodimer to Hormone Response Element-- The above results were of interest because the DNA binding domain of RXR has been reported to be involved in the formation of TR/RXR heterodimers on direct repeat DNA element. To characterize further interaction between Oct-1 and receptor heterodimers, we performed gel mobility shift assays using bacterially expressed and purified TR and RXR. The results shown in Fig. 3 indicated that addition of increasing amounts of bacterially expressed and purified GST-Oct-1 POU domain attenuated the binding of RXR/TR heterodimers to TRE (lanes 4 and 5), whereas addition of GST alone did not alter the binding (lane 3). The DNA binding activity of TR/RXR heterodimers was decreased by addition of GST-Oct-1 POU domain. These results showed that association of Oct-1 to RXR inhibited the RXR/TR heterodimers from binding to DNA elements.


View larger version (78K):
[in this window]
[in a new window]
  		Fig. 3.   Oct-1 POU domain reduced the TR/RXR heterodimer binding to DR4 element. Bacterially expressed and purified RXR and TR were incubated with radiolabeled DR4 probe in the presence of 1 (lane 4) and 5 mg (lane 5) of GST-Oct-1 POU domain or 5 µg of GST alone (lane 3). DR4 element comprises AGGTCA direct repeat spaced by four nucleotides in a gel retardation assay. Positions of RXR/TR heterodimer, TR/TR homodimer, and TR monomer binding were indicated by arrows.

Oct-1/2 Represses the Hormone-dependent Transcriptional Activity-- To test the possible role of Oct-1 and Oct-2 in T3-dependent transcriptional activation, we performed transient transfection experiments in COS1 cells. Full length Oct-1 or Oct-2 expression vectors or empty expression vectors were co-transfected with a luciferase reporter plasmid containing two copies of the TR response element into COS1 cells. After 12 h, cells were harvested, and luciferase activities were determined. As shown in Fig. 4, both Oct-1 and Oct-2 repressed the T3-dependent transcriptional activity. In the presence of T3, co-expression of Oct-1 decreased the TR activity by approximately 40% and Oct-2 by approximately 30%. Co-expression of Oct-1/2 did not influence the amount of expression of TR when determined by T3 binding assay. Furthermore, Oct-1/2 had little effect on cytomegalovirus promoter (data not shown). These data suggest that Oct-1 can function as a co-repressor for the T3-dependent transcriptional activity of the TR/RXR heterodimers. We next examined the effect of Oct-1 expression on naturally occurring T3-responsive promoter. As shown in Fig. 4B, rat growth hormone promoter, which was one of a well characterized T3-responsive promoter, was inhibited in a similar manner, suggesting the physiological relevance of the inhibitory role of Oct-1 in T3-dependent transcription.


View larger version (26K):
[in this window]
[in a new window]
  		Fig. 4.   Role of interaction in ligand-dependent activation by nuclear receptor. 0.1 µg of control vector, Oct-1, or Oct-2 expression vector were co-transfected into COS1 cells with 0.25 µg of Palx2TK luciferase (Luc) reporter (A) or rGHTRE TK chloramphenicol acetyltransferase (CAT) reporter (B) and 0.1 µg of TRalpha 1 expression vector. Relative luciferase activities and chloramphenicol acetyltransferase activity in the absence (solid bar) or presence (hatched bar) of T3 (10-7 M) are presented after being normalized by the internal control beta -galactosidase activities. Each transfection was conducted in triplicate, and data represent the mean ± S.D. of more than three individual experiments. HA, hemagglutinin.

Oct-1/2 Also Interact with TR and VDR-- Because highly conserved DNA binding domain of RXR was involved in the interaction, it is likely that other nuclear receptors could also interact with Oct-1. We next examined the interaction of other nuclear receptor family members with Oct-1 and Oct-2. As we expected, both 35S-labeled Oct-1 and Oct-2 associated to matrix-bound TR and VDR as well as RXR (Fig. 5A). In order to confirm the heterodimerization ability of GST fusion proteins with RXR, 35S-labeled RXR was incubated with matrix-bound GST fusions (lanes 11-15). Significant associations were detected with GST-TR and GST-VDR, whereas only weak association was detected with GST-RXR, consistent with previous data showing preference of heterodimerization of RXR. We next tested whether Oct-1 can interact with irrelevant DNA-binding transcription factor AP-2. As shown in Fig. 5B, 35S-labeled Oct-1 did not bind to the GST-AP-2, whereas significant amounts of 35S-labeled Oct-1 associated with GST-RXR, suggesting the specific interaction of Oct-1 with nuclear receptors.


View larger version (27K):
[in this window]
[in a new window]
  		Fig. 5.   Both Oct-1 and Oct-2 interact with TR and VDR as well as RXR. A, 35S-labeled Oct-1, Oct-2, and RXRalpha were synthesized by in vitro translation and incubated separately with GST (lanes 2, 7, and 12), GST-RXR (lanes 3, 8, and 13), GST-TR (lane 4, 9 and 14), or GST-VDR (lanes 5, 10, and 15) bound to glutathione-Sepharose beads. 10% input from the 35S-labeled proteins is indicated (lanes 1, 6, and 11). B, 35S-labeled Oct-1 was separately incubated with GST (lane 2), GST-RXR (lane 3), and GST-AP-2 (lane 4) affinity matrixes. 10% of 35S-labeled proteins added to the incubations is indicated (lane 1).

Oct-1 Did Not Influence the Transcriptional Activation by Gal4-TR(LBD) Fusion Protein-- We further investigated the effect of Oct-1 on transcriptional activation by Gal4-TR(LBD) which lacks its own DNA binding domain but retains responsiveness to T3. As shown in Fig. 6, Oct-1 did not influence the transcriptional activation by Gal4-TRalpha (LBD) fusion protein on upstream activating sequence luciferase reporter. These data are consistent with in vitro results showing that Oct-1 interacted with nuclear receptors via their DNA binding domain and inhibited their DNA binding activity. The DNA binding domain of nuclear receptor was required for the inhibitory effect of Oct-1.


View larger version (31K):
[in this window]
[in a new window]
  		Fig. 6.   Oct-1 did not influence the transcriptional activation by Gal4-TR(LBD) fusion protein. 0.1 µg of control vector, Oct-1, or Oct-2 expression vector was co-transfected into COS1 cells with 0.25 µg of UASx4 TK luciferase (Luc) reporter and 0.1 µg of pMTRalpha 1(LBD) expression vector. Relative luciferase activities in the absence (solid bar) or presence (hatched bar) of T3 (10-7 M) are presented after being normalized by the internal control beta -galactosidase activities. Each transfection was conducted in triplicate, and data represent the mean ± S.D. of more than three individual experiments.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

In this study, we have examined the interaction between RXR and POU domain of Oct-1. Our results indicated that Oct-1 interacted with nuclear receptors by direct protein-protein interaction and influenced the ligand-dependent transcriptional activity of nuclear receptors.

Recent data show that nuclear receptor co-activators such as SRC-1 and CBP/p300 recruit histone acetyltransferase, p/CAF, and pCIP to DNA-bound nuclear receptors and lead to the unfolding of the DNA-core histone complex (22-24, 51). In addition to co-activators, nuclear receptor co-repressor N-CoR and related factor SMRT, which were initially discovered through their ability to bind to unliganded nuclear receptors, recruit histone deacetylase (mSin3 and mRPD3) and result in the condensation of the chromatin structure to repress the basal transcription (14, 12, 52). Co-activator and co-repressor interact with the ligand binding domain and hinge domain of nuclear receptors, respectively. So far, little is known about potential role of the DNA binding region of nuclear receptors on transcriptional regulation. We report here the identification of the transcription factor Oct-1/2 as a binding protein for the DNA binding domain (DBD) of RXR and influence on ligand-dependent transcriptional activity of nuclear receptors. The highly conserved DBD of nuclear receptors could also serve as a site of interaction for co-regulator proteins, suggesting that Oct-1/2 function is analogous among the members of the nuclear receptors. Our results demonstrated that the POU homeodomain of Oct-1, which is known to form a complex with the herpes simplex virus transactivator VP16 (53), was involved in the interaction with RXR. POU homeodomains have been shown to be involved in protein-protein interaction as well as sequence-specific DNA binding. A number of transcription factors have been identified to interact with the POU domains of Oct-1 and/or Oct-2, e.g. TBP, TFIIB, HMG2, the lymphoid-specific transcriptional co-activator OBF-1 (30-34). Recently, it has been reported that glucocorticoid receptor interacts with the POU domain of Oct-1 and modulates the ligand-dependent transcriptional activity of glucocorticoid receptor (54, 55). Furthermore, Budhram et al. (56) also reported that the POU domains of Brn-3a and Brn-3b, which belong to the POU family of transcription factors, interact with estrogen receptor (ER) and regulate transcriptional activity of ER. It also has been demonstrated that POU transcription factor Pit-1 interacts with TR to activate growth hormone gene transcription (57) and with ER to modulate expression of the prolactin promoter in pituitary cells (58, 59).

Herein, our results showed that the Oct-1 POU domain interacted with DBD of RXR and prevented TR/RXR heterodimers from binding to TRE. These results were consistent with transient transfection experiments showing that co-transfection of Oct-1 expression vector significantly inhibited the ligand-dependent activation by nuclear receptors. An inhibiting effect of Oct-1 could not be observed on thyroid hormone responsiveness mediated by Gal4-TR(LBD) fusion that lacks its DNA binding domain but retains its T3 responsiveness. We concluded that Oct-1 negatively regulates nuclear receptor transcriptional activity by competitive binding to DBD of receptors with DNA elements.

Since Segil et al. (60) reported that phosphorylation of the POU homeodomain of Oct-1 correlates with DNA binding and cell cycle regulation of gene transcription, it is tempting to speculate that phosphorylation of POU domain of Oct-1 may regulate the transcriptional activity of nuclear receptors via altering the interaction with RXR. As expression and activity of Oct-1 are differentially regulated in development, differentiation, and cell cycle regulation, nuclear receptor signaling is also controlled via the Oct-1 pathway at these physiological conditions. Furthermore, recent data showed that transcriptional activity of Pit-1 is determined by a regulated balance between a co-repressor complex that contains N-CoR/SMRT, mSin3, and histone deacetylase and a co-activator complex that contains the CBP and p/CAF (61). Since these co-repressors and co-activators also interact with nuclear receptors, complex and promiscuous cross-talk between POU transcription factors and nuclear receptors can be expected. It would also be of interest to examine the role of nuclear receptors in the transcriptional activity of Oct-1 on the octamer-binding site.

    ACKNOWLEDGEMENTS

We thank Dr. R. M. Evans for providing RXRalpha cDNA and Dr. B. O'Malley for the gift of VDR cDNA. We also thank Dr. W. Herr, Dr. H. Singh, and Dr. R. G. Roeder for providing Oct-1/2 cDNA. We thank Dr. P. C. van der Vliet for providing eukaryotic expression plasmids for the Oct-1 POU domain, the POU homeodomain, and the POU-specific domain.

    FOOTNOTES

* This study was supported in part by a grant from the Ministry of Education, Japan.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger To whom correspondence should be addressed: Dept. of Geriatrics, Endocrinology and Metabolism, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto, 390-8621 Japan. Tel.: +81-263-37-2686; Fax: +81-263-37-2710; E-mail: tkaki{at}hsp.md.shinshu-u.ac.jp.

    ABBREVIATIONS

The abbreviations used are: TR, thyroid hormone receptor; RXR, retinoid X receptor; VDR, vitamin D receptor; ER, estrogen receptor; Oct-1, octamer transcription factor-1; DBD, DNA binding domain; GST, glutathione S-transferase; T3, 3,3',5tri-iodo-L-thyronine; TRE, thyroid hormone response element; PCR, polymerase chain reaction; PBS, phosphate-buffered saline; TK, thymidine kinase; N-CoR, nuclear receptor co-repressor; rGH, rat growth hormone; LBD, ligand binding domain.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
  1. Evans, R. M. (1988) Science 240, 889-895[Abstract/Free Full Text]
  2. Mangelsdorf, D. J., Thummel, C., Beato, M., Herrlich, P., Schutz, G., Umesono, K., Blumberg, B., Kastner, P., Mark, M., Chambon, P., and Evans, R. M. (1995) Cell 83, 835-839[CrossRef][Medline] [Order article via Infotrieve]
  3. Mangelsdorf, D. J., and Evans, R. M. (1995) Cell 83, 841-850[CrossRef][Medline] [Order article via Infotrieve]
  4. Evans, R. M., and Hollenberg, S. M. (1988) Cell 52, 1-3[CrossRef][Medline] [Order article via Infotrieve]
  5. Carson, J. M., Schrader, W. T., and O'Malley, B. W. (1990) Endocr. Rev. 11, 201-220[Abstract]
  6. Brent, G. A., Harney, J. W., Chen, Y., Warne, R. L., Moore, D. D., and Larsen, P. R. (1989) Mol. Endocrinol. 3, 1996-2004[Abstract]
  7. Glass, C. K., Holloway, J. M., Devary, O. V., and Rosenfeld, M. G. (1988) Cell 54, 313-323[CrossRef][Medline] [Order article via Infotrieve]
  8. Yu, V. C., Delsert, C., Andersen, B., Holloway, J. M., Devary, O. V., Naar, A. M., Kim, S. Y., Boutin, J. M., Glass, C. K., and Rosenfeld, M. G. (1991) Cell 67, 1251-1266[CrossRef][Medline] [Order article via Infotrieve]
  9. Kliewer, S. A., Umesono, K., Mangelsdorf, D. J., and Evans, R. M. (1992) Nature 355, 446-449[CrossRef][Medline] [Order article via Infotrieve]
  10. Zhang, X. K., Hoffmann, B., Tran, P. B., Graupner, G., and Pfahl, M. (1992) Nature 355, 441-446[CrossRef][Medline] [Order article via Infotrieve]
  11. Chen, J. D., and Evans, R. M. (1995) Nature 377, 454-457[CrossRef][Medline] [Order article via Infotrieve]
  12. Nagy, L., Kao, H. Y., Chakravarti, D., Lin, R. J., Hassig, C. A., Ayer, D. E., Schreiber, S. L., and Evans, R. M. (1997) Cell 89, 373-380[CrossRef][Medline] [Order article via Infotrieve]
  13. Glass, C. K., Rose, D. W., and Rosenfeld, M. G. (1997) Curr. Opin. Cell Biol. 9, 222-232[CrossRef][Medline] [Order article via Infotrieve]
  14. Heinzel, T., Lavinsky, R. M., Mullen, T. M., Soderstrom, M., Laherty, C. D., Torchia, J., Yang, W. M., Brard, G., Ngo, S. D., Davie, J. R., Seto, E., Eisenman, R. N., Rose, D. W., Glass, C. K., and Rosenfeld, M. G. (1997) Nature 387, 43-48[CrossRef][Medline] [Order article via Infotrieve]
  15. Onate, S. A., Tsai, S. Y., Tsai, M. J., and O'Malley, B. W. (1995) Science 270, 1354-1357[Abstract/Free Full Text]
  16. Chakravarti, D., LaMorte, V. J., Nelson, M. C., Nakajima, T., Schulman, I. G., Juguilon, H., Montminy, M., and Evans, R. M. (1996) Nature 383, 99-103[CrossRef][Medline] [Order article via Infotrieve]
  17. Voegel, J. J., Heine, M. J., Zechel, C., Chambon, P., and Gronemeyer, H. (1996) EMBO J. 15, 3667-3675[Medline] [Order article via Infotrieve]
  18. Smith, C. L., Onate, S. A., Tsai, M. J., and O'Malley, B. W. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 8884-8888[Abstract/Free Full Text]
  19. Yao, T. P., Ku, G., Zhou, N., Scully, R., and Livingston, D. M. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 10626-10631[Abstract/Free Full Text]
  20. Kamei, Y., Xu, L., Heinzel, T., Torchia, J., Kurokawa, R., Gloss, B., Lin, S. C., Heyman, R. A., Rose, D. W., Glass, C. K., and Rosenfeld, M. G. (1996) Cell 85, 403-414[CrossRef][Medline] [Order article via Infotrieve]
  21. Torchia, J., Rose, D. W., Inostroza, J., Kamei, Y., Westin, S., Glass, C. K., and Rosenfeld, M. G. (1997) Nature 387, 677-684[CrossRef][Medline] [Order article via Infotrieve]
  22. Bannister, A. J., and Kouzarides, T. (1996) Nature 384, 641-643[CrossRef][Medline] [Order article via Infotrieve]
  23. Ogryzko, V. V., Schiltz, R. L., Russanova, V., Howard, B. H., and Nakatani, Y. (1996) Cell 87, 953-959[CrossRef][Medline] [Order article via Infotrieve]
  24. Spencer, T. E., Jenster, G., Burcin, M. M., Allis, C. D., Zhou, J., Mizzen, C. A., McKenna, N. J., Onate, S. A., Tsai, S. Y., Tsai, M. J., and O'Malley, B. W. (1997) Nature 389, 194-198[CrossRef][Medline] [Order article via Infotrieve]
  25. Fletcher, C., Heintz, N., and Roeder, R. G. (1987) Cell 51, 773-781[CrossRef][Medline] [Order article via Infotrieve]
  26. Sturm, R. A., Das, G., and Herr, W. (1988) Genes Dev. 2, 1582-1599[Abstract/Free Full Text]
  27. Murphy, S., Yoon, J. B., Gerster, T., and Roeder, R. G. (1992) Mol. Cell. Biol. 12, 3247-3261[Abstract/Free Full Text]
  28. Herr, W., Sturm, R. A., Clerc, R. G., Corcoran, L. M., Baltimore, D., Sharp, P. A., Ingraham, H. A., Rosenfeld, M. G., Finney, M., and Ruvkun, G. (1988) Genes Dev. 2, 1513-1516[Free Full Text]
  29. Sturm, R. A., and Herr, W. (1988) Nature 336, 601-604[CrossRef][Medline] [Order article via Infotrieve]
  30. Zwilling, S., Annweiler, A., and Wirth, T. (1994) Nucleic Acids Res. 22, 1655-1662[Abstract/Free Full Text]
  31. Nakshatri, H., Nakshatri, P., and Currie, R. A. (1995) J. Biol. Chem. 270, 19613-19623[Abstract/Free Full Text]
  32. Zwilling, S., Konig, H., and Wirth, T. (1995) EMBO J. 14, 1198-1208[Medline] [Order article via Infotrieve]
  33. Gstaiger, M., Georgiev, O., van Leeuwen, H., van der Vliet, P. C., and Schaffner, W. (1996) EMBO J. 15, 2781-2790[Medline] [Order article via Infotrieve]
  34. Wong, M. W., Henry, R. W., Ma, B., Kobayashi, R., Klages, N., Matthias, P., Strubin, M., and Hernandez, N. (1998) Mol. Cell. Biol. 18, 368-377[Abstract/Free Full Text]
  35. Wirth, T., Staudt, L., and Baltimore, D. (1987) Nature 329, 174-178[CrossRef][Medline] [Order article via Infotrieve]
  36. Scheidereit, C., Cromlish, J. A., Gerster, T., Kawakami, K., Balmaceda, C. G., Currie, R. A., and Roeder, R. G. (1988) Nature 336, 551-557[CrossRef][Medline] [Order article via Infotrieve]
  37. Muller, M. M., Ruppert, S., Schaffner, W., and Matthias, P. (1988) Nature 336, 544-551[CrossRef][Medline] [Order article via Infotrieve]
  38. Shah, P. C., Bertolino, E., and Singh, H. (1997) EMBO J. 16, 7105-7117[CrossRef][Medline] [Order article via Infotrieve]
  39. Inamoto, S., Segil, N., Pan, Z. Q., Kimura, M., and Roeder, R. G. (1997) J. Biol. Chem. 272, 29852-29858[Abstract/Free Full Text]
  40. Coenjaerts, F. E., van Oosterhout, J., and van der Vliet, P. C. (1994) EMBO J. 13, 5401-5409[Medline] [Order article via Infotrieve]
  41. Mangelsdorf, D. J., Ong, E. S., Dyck, J. A., and Evans, R. M. (1990) Nature 345, 224-229[CrossRef][Medline] [Order article via Infotrieve]
  42. Baker, A. R., McDonnell, D. P., Hughes, M., Crisp, T. M., Mangelsdorf, D. J., Haussler, M. R., Pike, J. W., Shine, J., and O'Malley, B. W. (1988) Proc. Natl. Acad. Sci. U. S. A. 85, 3294-3298[Abstract/Free Full Text]
  43. Miyamoto, T., Sakurai, A., and DeGroot, L. J. (1991) Endocrinology 129, 3027-3033[Abstract]
  44. Williams, T., Admon, A., Luscher, B., and Tjian, R. (1998) Genes Dev. 2, 1557-1569[Abstract/Free Full Text]
  45. Nakai, A., Sakurai, A., Bell, G. I., and DeGroot, L. J. (1988) Mol. Endocrinol. 2, 1087-1092[Abstract]
  46. Nagaya, T., and Jameson, J. L. (1993) J. Biol. Chem. 268, 15766-15771[Abstract/Free Full Text]
  47. Larsen, P. R., Harney, J. W., and Moore, D. D. (1986) Proc. Natl. Acad. Sci. U. S. A. 83, 8283-8287[Abstract/Free Full Text]
  48. Forman, B. M., Umesono, K., Chen, J., and Evans, R. M. (1995) Cell 81, 541-550[CrossRef][Medline] [Order article via Infotrieve]
  49. Miyamoto, T., Kaneko, A., Kakizawa, T., Yajima, H., Kamijo, K., Sekine, R., Hiramatsu, K., Nishii, Y., Hashimoto, T., and Hashizume, K. (1997) J. Biol. Chem. 272, 7752-7758[Abstract/Free Full Text]
  50. Miyamoto, T., Suzuki, S., and DeGroot, L. J. (1994) Mol. Cell. Endocrinol. 102, 111-117[CrossRef][Medline] [Order article via Infotrieve]
  51. Chen, H., Lin, R. J., Schiltz, R. L., Chakravarti, D., Nash, A., Nagy, L., Privalsky, M. L., Nakatani, Y., and Evans, R. M. (1997) Cell 90, 569-580[CrossRef][Medline] [Order article via Infotrieve]
  52. Soderstrom, M., Vo, A., Heinzel, T., Lavinsky, R. M., Yang, W. M., Seto, E., Peterson, D. A., Rosenfeld, M. G., and Glass, C. K. (1997) Mol. Endocrinol. 11, 682-692[Abstract/Free Full Text]
  53. Stern, S., Tanaka, M., and Herr, W. (1989) Nature 341, 624-630[CrossRef][Medline] [Order article via Infotrieve]
  54. Kutoh, E., Stromstedt, P. E., and Poellinger, L. (1992) Mol. Cell. Biol. 12, 4960-4969[Abstract/Free Full Text]
  55. Prefontaine, G. G., Lemieux, M. E., Giffin, W., Schild, P. C., Pope, L., LaCasse, E., Walker, P., and Hache, R. J. (1998) Mol. Cell. Biol. 18, 3416-3430[Abstract/Free Full Text]
  56. Budhram, M. V., Parker, M., and Latchman, D. S. (1998) Mol. Cell. Biol. 18, 1029-1041[Abstract/Free Full Text]
  57. Chang, W., Zhou, W., Theill, L. E., Baxter, J. D., and Schaufele, F. (1996) J. Biol. Chem. 271, 17733-17738[Abstract/Free Full Text]
  58. Day, R. N., Koike, S., Sakai, M., Muramatsu, M., and Maurer, R. A. (1990) Mol. Endocrinol. 4, 1964-1971[Abstract]
  59. Holloway, J. M., Szeto, D. P., Scully, K. M., Glass, C. K., and Rosenfeld, M. G. (1995) Genes Dev. 9, 1992-2006[Abstract/Free Full Text]
  60. Segil, N., Roberts, S. B., and Heintz, N. (1991) Science 254, 1814-1816[Abstract/Free Full Text]
  61. Xu, L., Lavinsky, R. M., Dasen, J. S., Flynn, S. E., McInerney, E. M., Mullen, T. M., Heinzel, T., Szeto, D., Korzus, E., Kurokawa, R., Aggarwal, A. K., Rose, D. W., Glass, C. K., and Rosenfeld, M. G. (1998) Nature 395, 301-306[CrossRef][Medline] [Order article via Infotrieve]

Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 J. Biol. Chem.Home page
N. G. d. Paz, S. Simeonidis, C. Leo, D. W. Rose, and T. Collins
Regulation of NF-{kappa}B-dependent Gene Expression by the POU Domain Transcription Factor Oct-1
J. Biol. Chem., March 16, 2007; 282(11): 8424 - 8434.
[Abstract] [Full Text] [PDF]

Home page
 Genes Dev.Home page
R. Grosskortenhaus, K. J. Robinson, and C. Q. Doe
Pdm and Castor specify late-born motor neuron identity in the NB7-1 lineage
Genes & Dev., September 15, 2006; 20(18): 2618 - 2627.
[Abstract] [Full Text] [PDF]

Home page
 DevelopmentHome page
I. Foucher, M. L. Montesinos, M. Volovitch, A. Prochiantz, and A. Trembleau
Joint regulation of the MAP1B promoter by HNF3{beta}/Foxa2 and Engrailed is the result of a highly conserved mechanism for direct interaction of homeoproteins and Fox transcription factors
Development, May 1, 2003; 130(9): 1867 - 1876.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
S. Boulon, J.-C. Dantonel, V. Binet, A. Vie, J.-M. Blanchard, R. A. Hipskind, and A. Philips
Oct-1 Potentiates CREB-Driven Cyclin D1 Promoter Activation via a Phospho-CREB- and CREB Binding Protein-Independent Mechanism
Mol. Cell. Biol., November 15, 2002; 22(22): 7769 - 7779.
[Abstract] [Full Text] [PDF]

Home page
 Hum Mol GenetHome page
D. A. van Heel, I. A. Udalova, A. P. De Silva, D. P. McGovern, Y. Kinouchi, J. Hull, N. J. Lench, L. R. Cardon, A. H. Carey, D. P. Jewell, et al.
Inflammatory bowel disease is associated with a TNF polymorphism that affects an interaction between the OCT1 and NF-{kappa}B transcription factors
Hum. Mol. Genet., May 16, 2002; 11(11): 1281 - 1289.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
J.-i. Mori, S. Suzuki, M. Kobayashi, T. Inagaki, A. Komatsu, T. Takeda, T. Miyamoto, K. Ichikawa, and K. Hashizume
Nicotinamide Adenine Dinucleotide Phosphate-Dependent Cytosolic T3 Binding Protein as a Regulator for T3-Mediated Transactivation
Endocrinology, April 1, 2002; 143(4): 1538 - 1544.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
B. Andersen and M. G. Rosenfeld
POU Domain Factors in the Neuroendocrine System: Lessons from Developmental Biology Provide Insights into Human Disease
Endocr. Rev., February 1, 2001; 22(1): 2 - 35.
[Abstract] [Full Text]

Home page
 Cancer Res.Home page
H. Zhao, S. Jin, F. Fan, W. Fan, T. Tong, and Q. Zhan
Activation of the Transcription Factor Oct-1 in Response to DNA Damage
Cancer Res., November 1, 2000; 60(22): 6276 - 6280.
[Abstract] [Full Text]

Home page
 J. Biol. Chem.Home page
T. Kakizawa, T. Miyamoto, K. Ichikawa, T. Takeda, S. Suzuki, J.-i. Mori, M. Kumagai, K. Yamashita, and K. Hashizume
Silencing Mediator for Retinoid and Thyroid Hormone Receptors Interacts with Octamer Transcription Factor-1 and Acts as a Transcriptional Repressor
J. Biol. Chem., March 23, 2001; 276(13): 9720 - 9725.
[Abstract] [Full Text] [PDF]

This Article